MitrAssist Overview
MitrAssist has developed an approach to treating patients with life-threatening mitral regurgitation (MR) that involves neither repair nor replacement. Instead, the companys proprietary valve implant is placed on top of the natural valve to work in unison with it and to enhance valve functionality. MitrAssists valve-in-valve approach overcomes the various challenges of MR and offers an alternative treatment solution for all MR patients. Made from biomedical and biological materials, MitrAssists valve offers improved biocompatibility and patient recovery time.
Cumulative Funding Raised Over Time ($)
$70.0MDec 2020
$73.0MJan 2014
$74.0MJul 2013
$174.0MJul 2023
$204.0MNov 2017
Latest News
growth-positive
Centurium, 6 Dimensions lead $100m Series C round for medtech startup MitrAssist
MitrAssist, an Israel-based medical devices developer, has raised nearly $100 million in a Series C funding round to accelerate the R&D and commercialisation of its cardiovascular technologies. The round was led by existing shareholders Centurium Capital and 6 Dimensions Capital. Other participants included state capital investors from the Jiading District of Shanghai and Haiheng Investment, as well as Hefei Industry Investment Group and other domestic investors. MitrAssist, which is expanding in China, develops a minimally invasive mitral valve implant to enhance the valves functionality and prevent the need for complete valve replacement.
InvestmentExpand
growth-positive
Shanghai MITRASSIST Medical Closes Nearly $100 Million Series C Financing - G-MedTech News Center
Shanghai-based MITRASSIST Medical has raised nearly $100 million in a Series C financing round led by Centurium Capital and 6 Dimensions Capital, with participation from several other investors. The funds will be used for the development and commercialization of mitral valve replacement products and aortic polymer valve products. The company, which specializes in innovative cardiovascular medical devices, recently signed an agreement to invest $270 million in Hefei City, Anhui Province, to establish a research and development, production and commercialisation base for cardiovascular products and high-value consumables.
InvestmentExpand
growth-positive
Israeli medical valve co MitrAssist raises $50m
Israeli medical device company MitrAssist has raised $50 million in a funding round, bringing the total amount raised by the company to $85 million. The funding round included current investors Chinese Fosun Pharma and insurance company Ping-An, as well as four large Chinese funds. MitrAssist, which has developed a medical valve for symptomatic patients with primary or secondary mitral regurgitation, plans to use the funding to complete clinical trials and reach the Chinese market by 2024. The company also plans to hire more employees in early 2021 to develop more ideas in the field of structural heart diseases.
InvestmentExpand
growth-positive
Heart Valve Company MitrAssist Raises $30M
Israeli biotech company MitrAssist has raised $30 million in a funding round led by Fosun Pharma and Ping An Insurance Company. The company, which developed a heart valve implant that can be installed through a thigh catheterization, received $16 million based on its pre-closing valuation of $80 million. It will receive an additional $14 million when it begins clinical trials within a year, based on a pre-closing valuation of $136 million. MitrAssist was founded in 2009 by Gil Naor.
Investment
growth-positive
Fosun Leads $30 Million Round for Heart Valve Company MitrAssist
MitrAssist Ltd, an Israel-based biotech company, has raised $30 million in an investment round led by Fosun Pharma and participated by Ping An Insurance Company of China. The company has developed a valve implant that can be installed through thigh catheterization, providing a less invasive alternative to heart surgery. MitrAssist aims to treat mitral regurgitation, a prevalent heart valve disease in the US. The investment will be used for clinical trials, with $16 million received initially and an additional $14 million expected when the trials begin. MitrAssist plans to market its valve in Europe first and is already in contact with regulatory authorities and doctors in Germany and New York.
InvestmentExpand
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $204M |
| Last funding | $100M |
| Stage | C |
| Rounds | 5 |
| Investors | 7 |
Team Members
1
Employees: 1-10
Web & Social Links
| Website | mitrassist.com |
Locations
Alon Hatavor 20, Caesarea, Israel
Photos & Videos
No files yet
MitrAssist Business
Business models
B2B
Product stage
Clinical Trial
Employees
1-10
Sector
Health Tech & Life SciencesMedical DevicesMedical Treatment & TherapeuticsTarget Customer
Healthcare & Life SciencesHealthcareProvidersCore Technology
Materials & SubstancesImplantsTags (8)
cardiologyhospitalsdoctorsbiomaterialssurgerymedical-devicesvalvesminimally-invasiveGeographic Markets
GlobalMitrAssist Financials
$204M
Total funding
Undisclosed
Capital raised
$100M
Last funding
C
Funding stage
5
Total rounds
7
Investors
Cumulative Funding Raised Over Time ($)
$70.0MDec 2020
$73.0MJan 2014
$74.0MJul 2013
$174.0MJul 2023
$204.0MNov 2017
Private Equity Funding
C Round
Jul 2023
$100M
Centurium Capital (Lead), 6 Dimension Capital (Lead)
B Round
Dec 2020
$70M
Centurium Capital (Lead)
,
Fosun Pharma, Ping An Ventures, 6 Dimension Capital , CITIC Capital, CICC Capital
A Round
Nov 2017
$30M
Fosun Pharma, Ping An Ventures
A Round
Jan 2014
$3M
LongTec HongTao China Ventures
Seed
Jul 2013
$1M
MitrAssist Lifecycle
Cumulative Funding Raised Over Time
$70.0MDec 2020
$73.0MJan 2014
$74.0MJul 2013
$174.0MJul 2023
$204.0MNov 2017
All Events
C Round
Jul 2023
$100M
Centurium Capital (Lead), 6 Dimension Capital (Lead)
B Round
Dec 2020
$70M
Centurium Capital (Lead)
,
Fosun Pharma, Ping An Ventures, 6 Dimension Capital , CITIC Capital, CICC Capital
A Round
Nov 2017
$30M
Fosun Pharma, Ping An Ventures
A Round
Jan 2014
$3M
LongTec HongTao China Ventures
Seed
Jul 2013
$1M
MitrAssist News
7 articles
growth-positive
Centurium, 6 Dimensions lead $100m Series C round for medtech startup MitrAssist
MitrAssist, an Israel-based medical devices developer, has raised nearly $100 million in a Series C funding round to accelerate the R&D and commercialisation of its cardiovascular technologies. The round was led by existing shareholders Centurium Capital and 6 Dimensions Capital. Other participants included state capital investors from the Jiading District of Shanghai and Haiheng Investment, as well as Hefei Industry Investment Group and other domestic investors. MitrAssist, which is expanding in China, develops a minimally invasive mitral valve implant to enhance the valves functionality and prevent the need for complete valve replacement.
InvestmentExpand
growth-positive
Shanghai MITRASSIST Medical Closes Nearly $100 Million Series C Financing - G-MedTech News Center
Shanghai-based MITRASSIST Medical has raised nearly $100 million in a Series C financing round led by Centurium Capital and 6 Dimensions Capital, with participation from several other investors. The funds will be used for the development and commercialization of mitral valve replacement products and aortic polymer valve products. The company, which specializes in innovative cardiovascular medical devices, recently signed an agreement to invest $270 million in Hefei City, Anhui Province, to establish a research and development, production and commercialisation base for cardiovascular products and high-value consumables.
InvestmentExpand
growth-positive
Israeli medical valve co MitrAssist raises $50m
Israeli medical device company MitrAssist has raised $50 million in a funding round, bringing the total amount raised by the company to $85 million. The funding round included current investors Chinese Fosun Pharma and insurance company Ping-An, as well as four large Chinese funds. MitrAssist, which has developed a medical valve for symptomatic patients with primary or secondary mitral regurgitation, plans to use the funding to complete clinical trials and reach the Chinese market by 2024. The company also plans to hire more employees in early 2021 to develop more ideas in the field of structural heart diseases.
InvestmentExpand
growth-positive
Heart Valve Company MitrAssist Raises $30M
Israeli biotech company MitrAssist has raised $30 million in a funding round led by Fosun Pharma and Ping An Insurance Company. The company, which developed a heart valve implant that can be installed through a thigh catheterization, received $16 million based on its pre-closing valuation of $80 million. It will receive an additional $14 million when it begins clinical trials within a year, based on a pre-closing valuation of $136 million. MitrAssist was founded in 2009 by Gil Naor.
Investment
growth-positive
Fosun Leads $30 Million Round for Heart Valve Company MitrAssist
MitrAssist Ltd, an Israel-based biotech company, has raised $30 million in an investment round led by Fosun Pharma and participated by Ping An Insurance Company of China. The company has developed a valve implant that can be installed through thigh catheterization, providing a less invasive alternative to heart surgery. MitrAssist aims to treat mitral regurgitation, a prevalent heart valve disease in the US. The investment will be used for clinical trials, with $16 million received initially and an additional $14 million expected when the trials begin. MitrAssist plans to market its valve in Europe first and is already in contact with regulatory authorities and doctors in Germany and New York.
InvestmentExpand
growth-positive
Heart valve implant co MitrAssist raises $1m
MitrAssist, a portfolio company of Trendlines Group Ltd., has raised $1 million from angel investors and a multinational private strategic investor. The company has developed a minimally invasive approach to treating heart disorders where the mitral valve does not close properly. The raised funds will be used to complete transapical chronic studies on animals, which is the companys next milestone. MitrAssists approach brings an improved, safe, and cost-effective treatment solution for patients with mitral regurgitation, especially those who are unsuitable for open-heart surgery. The companys system preserves the natural mitral valve functionality and has minimal effect on heart physiology. The company aims to give hope to people who currently cannot undergo surgery due to their medical condition or age.
Investment
growth-positive
Minimally Invasive Treatment May Soon Be Possible For People With Mitral Regurgitation Disorder
Israeli company MitrAssist is developing an implant called MitraFix to treat mitral regurgitation, a disorder of the heart. The implant is designed to prevent leakage and restore normal blood flow, working in unison with the bodys own valve. MitrAssist aims to provide a solution for patients who are not eligible for surgery due to their medical condition or age. The company has raised $600,000 in funding, with $500,000 coming from The Trendlines Group and the rest from angel investors. MitrAssist plans to conduct its first clinical study of the device in 2016 and aims to raise an additional $5 million in Series A financing by the end of the year.
Investment
MitrAssist Team
Employee Info
| Employees (range) | 1-10 |
| Exact count | 3 |
| Team members | 1 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 8 classification IDs that could be used for matching.
MitrAssist Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 89/100 |
| Missing | video or image, markets, not claimed |
| BI Verification | Sharon Shapira |
| Registrar ID | 514263789 |
| Crunchbase | mitrassist |
| Phone | +972737803366 |
| Creator | Arielle Smolin |
| Creator email | ari.smolin@gmail.com |
| Last updater | Matan Eblagon |
| Updater email | matane@sncentral.org |
| Last update | 2023-10-01T00:00:00.000Z |
| Created | 2014-07-20T00:00:00.000Z |